Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $168.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price target upped by JPMorgan Chase & Co. from $167.00 to $168.00 in a research report report published on Thursday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

A number of other brokerages also recently commented on ASND. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Tuesday. Wedbush reaffirmed an “outperform” rating and set a $181.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. TD Cowen decreased their target price on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Finally, Oppenheimer dropped their price target on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $193.43.

Ascendis Pharma A/S Stock Performance

ASND stock opened at $142.49 on Thursday. The firm has a 50 day simple moving average of $132.19 and a 200 day simple moving average of $132.29. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $161.00. The stock has a market cap of $8.65 billion, a P/E ratio of -17.63 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. Sell-side analysts predict that Ascendis Pharma A/S will post -7.12 EPS for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Jump Financial LLC bought a new stake in Ascendis Pharma A/S during the 4th quarter valued at approximately $1,666,000. Guggenheim Capital LLC boosted its position in shares of Ascendis Pharma A/S by 256.9% in the fourth quarter. Guggenheim Capital LLC now owns 7,249 shares of the biotechnology company’s stock valued at $998,000 after acquiring an additional 5,218 shares during the period. Mariner LLC grew its stake in shares of Ascendis Pharma A/S by 31.0% in the fourth quarter. Mariner LLC now owns 2,160 shares of the biotechnology company’s stock worth $297,000 after acquiring an additional 511 shares during the last quarter. Sterling Capital Management LLC increased its position in Ascendis Pharma A/S by 19.0% during the fourth quarter. Sterling Capital Management LLC now owns 56,850 shares of the biotechnology company’s stock worth $7,827,000 after acquiring an additional 9,065 shares during the period. Finally, FIL Ltd increased its position in Ascendis Pharma A/S by 13.9% during the fourth quarter. FIL Ltd now owns 729,275 shares of the biotechnology company’s stock worth $100,399,000 after acquiring an additional 89,016 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.